Nocebo in Alzheimer's disease; Meta-analysis of placebo-controlled clinical trials

Journal of the Neurological Sciences

Volumn 355, Issue 1-2, 2015, Pages 94-100

  Zis, Panagiotis ^a   Mitsikostas, Dimos Dimitrios ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Adverse events; Alzheimer's disease; Dementia; Nocebo; Placebo; Trial design

Indexed keywords

PLACEBO; NEUROLEPTIC AGENT;

AGE; ALZHEIMER DISEASE; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; META ANALYSIS; NOCEBO EFFECT; PATIENT DROPOUTS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; MALE; MEDLINE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MEDLINE; NOCEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84937517143     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.05.029     Document Type: Article

References (28)

1. D.D. Mitsikostas, N.G. Chalarakis, L.I. Mantonakis, E.M. Delicha, and P.P. Sfikakis Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice Eur. J. Neurol. 19 5 May 2012 672 680
2. D.D. Mitsikostas, L. Mantonakis, and N. Chalarakis Nocebo in clinical trials for depression: a meta-analysis Psychiatry Res. 215 1 Jan 30 2014 82 86
3. P. Enck, F. Benedetti, and M. Schedlowski New insights into the placebo and nocebo responses Neuron 59 2008 195 206
4. A.J. Barsky, R. Saintfort, M.P. Rogers, and J.F. Borus Nonspecific medication side effects and the nocebo phenomenon JAMA 287 5 Feb 6 2002 622 627
5. F. Benedetti, M. Lanotte, L. Lopiano, and L. Colloca When words are painful: unraveling the mechanisms of the nocebo effect Neuroscience 147 2007 260 271
6. I. Tracey Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans Nat. Med. 16 11 Nov 2010 1277 1283
7. L. Manchikanti, J. Giordano, B. Fellows, and J.A. Hirsch Placebo and nocebo in interventional pain management: a friend or a foe - or simply foes? Pain Physician 14 2 Mar-Apr 2011 E157 E175
8. S. Elsenbruch, J. Schmid, M. Bäsler, E. Cesko, M. Schedlowski, and S. Benson How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women Neurogastroenterol. Motil. 24 10 Oct 2012 (914-e460)
9. D. Papadopoulos, and D.D. Mitsikostas Nocebo effects in multiple sclerosis trials: a meta-analysis Mult. Scler. 16 7 Jul 2010 816 828
10. D.D. Mitsikostas, L.I. Mantonakis, and N.G. Chalarakis Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches Cephalalgia 31 5 Apr 2011 550 561
11. D.D. Mitsikostas Nocebo in headaches: implications for clinical practice and trial design Curr. Neurol. Neurosci. Rep. 12 2 Apr 2012 132 137
12. D. Papadopoulos, and D.D. Mitsikostas A meta-analytic approach to estimating nocebo effects in neuropathic pain trials J. Neurol. 259 3 Mar 2012 436 447
13. W. Häuser, C. Bartram, E. Bartram-Wunn, and T. Tölle Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review Clin. J. Pain 28 5 Jun 2012 437 451
14. P. Stathis, M. Smpiliris, S. Konitsiotis, and D.D. Mitsikostas Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis Eur. J. Neurol. 20 3 Mar 2013 527 533
15. B.R. Rutherford, M.M. Wall, A. Glass, and J.W. Stewart The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry. 2014 Jun 10 J. Clin. Psychiatry 75 10 Oct 2014 1040 1046
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 2009 264 269
17. A.R. Jadad, R.A. Moore, D. Carroll, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17 1996 1 12
18. S.A. Olivo, L.G. Macedo, I.C. Gadotti, J. Fuentes, T. Stanton, and D.J. Magee Scales to assess the quality of randomized controlled trials: a systematic review Phys. Ther. 88 2008 156 175
19. W. Viechtbauer Conducting meta-analyses in R with the metafor package J. Stat. Softw. 36 2010 1 48
20. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat. Med. 21 2002 1539 1558
21. W.G. Cochran The combination of estimates from different experiments Biometrics 10 1954 100 129
22. J.P. Ioannidis Interpretation of tests of heterogeneity and bias in meta-analysis J. Eval. Clin. Pract. 14 2008 951 957
23. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
24. A.J. Sutton, Jones Abrams, T.A. Sheldon, and F. Song Systematic reviews of trials and other studies: meta-regression Health Technol. Assess. 2 1998 81 84
25. M. Amanzio, F. Benedetti, and L. Vase A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment Int. Psychogeriatr. 24 5 May 2012 698 707
26. M. Amanzio, L.L. Corazzini, L. Vase, and F. Benedetti A systematic review of adverse events in placebo groups of anti-migraine clinical trials Pain 146 3 Dec 2009 261 269
27. G.L. Petersen, N.B. Finnerup, L. Colloca, M. Amanzio, D.D. Price, T.S. Jensen, and L. Vase The magnitude of nocebo effects in pain: a meta-analysis Pain 155 8 Aug 2014 1426 1434
28. L. Colloca, and F.G. Miller The nocebo effect and its relevance for clinical practice Psychosom. Med. 73 7 Sep 2011 598 603